---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-25-087886"
form_type: "8-K"
ticker: "OTLK"
cik: "0001649989"
company_name: "Outlook Therapeutics, Inc."
filed_at: "2025-09-05T23:59:59+00:00"
generated_at: "2026-05-17T07:58:17.097234+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Chief Commercial Officer Jeff Evanson departs Outlook Therapeutics effective immediately

## Summary
- Jeff Evanson stepped down as Chief Commercial Officer on September 5, 2025.
- Departure is without 'cause'; eligible for severance benefits per employment agreement.
- No replacement named; interim CEO Lawrence Kenyon continues in role.
- Company is a biopharmaceutical firm focused on ophthalmic therapies.

## SEC filing metadata
- accession: 0001104659-25-087886
- form_type: 8-K
- ticker: OTLK
- cik: 0001649989
- company_name: Outlook Therapeutics, Inc.
- filed_at: 2025-09-05T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1649989/000110465925087886/0001104659-25-087886-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1649989/000110465925087886/tm2525276d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-25-087886
- JSON: https://secwatch.observer/filing/0001104659-25-087886.json
- Plain text: https://secwatch.observer/filing/0001104659-25-087886.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.